Kaplitt et al. 1995. Viral Vectors. Academic Press, Inc. San Diego, CA; pp. 215-216, and 229.* |
Dorland's Illustrated Medical Dictionary. 28th edition. W.B. Saunders Company. 1994. p. 1373.* |
Wintersperger et al. 1993 Journal of Cellular Biochemistry Supplement 17D p. 54, Mar. 1993.* |
Jane et al 1998 Annals of Medicine 30(5) 413-5, Oct. 1998.* |
Winslow, G.M., et al., “Processing and Major Histocompatibility Complex Binding of the MTV7 Superantigen,” Immunity, 1:23-33 (1994). |
Brandt-Carlson, C., et al., “Phylogenetic and Structural Analyses of MMTV LTR ORF Sequences of Exogenous and Endogenous Origins,” Virology, 193:171-185 (1993). |
Acha-Orbea, H., et al., “Subversion of host immune responses by viral superantigens,” Trends in Microbiol., 1:32-34 (1993). |
Mohan, N., et al., “Production and Characterization of an Mls-1-specific Monoclonal Antibody,” J. Exp. Med, 177:351-358 (1993). |
Krummenacher, C., et al., “The Mouse Mammary Tumor Virus Long Terminal Repeat Encodes a 47 kDa Glycoprotein with a Short Half-Life in Mammalian Cells,” Molecular Immunology, 30(13):1151-1157 (1993). |
Günzburg, W.H., et al., “Endogenous superantigen expression controlled by a novel promoter in the MMTV long terminal repeat,” Nature, 364:154-158 (1993). |
Winslow, G.M., et al., “Detection and Biochemical Characterization of the Mouse Mammary Tumor Virus 7 Superantigen (Mls-1a),” Cell, 71:719-730 (1992). |
Knight, A.M., et al., “Biochemical analysis of the mouse mammary tumor virus long terminal repeat product. Evidence for the molecular structure of an endogenous superantigen,” Eur. J. Immunol., 22:879-882 (1992). |
Korman, A.J., et al., “The mouse mammary tumour virus long terminal repeat encodes a type II transmembrane glycoprotein,” The EMBO Journal, 11(5):1901-1905 (1992). |
Huber, B.T., “Mls genes and self-superantigens,” TIG, 8(11):399-402 (1992). |
Pullen, A.M., et al., “The Open Reading Frames in the 3′ Long Terminal Repeats of Several Mouse Mammary Tumor Virus Integrants Encode Vβ3-specific Superantigens,” J. Exp. Med., 175:41-47 (1992). |
Günzburg, W.H., et al., “Factors controlling the expression of mouse mammary tumour virus,” Biochem. J., 283:625-632 (1992). |
Acha-Orbea, H., et al., “Clonal deletion of Vβ14-bearing T cells in mice transgenic for mammary tumour virus,” Nature, 350:207-211 (1991). |
Choi, Yongwon, et al., “A superantigen encoded in the open reading frame of the 3′ long terminal repeat of mouse mammary tumour virus,” Nature, 350:203-207 (1991). |
Brandt-Carlson, C., et al., “Detection and Characterization of a Glycoprotein Encoded by the Mouse Mammary Tumor Virus Long Terminal Repeat Gene,” Journal of Virology, 65(11):6051-6060 (1991). |
Salmons, B., et al., “Current perspectives in the biology of mouse mammary tumour virus,” Virus Research, 8:81-102 (1987). |
Salmons, B., et al., “naf, a trans-Regulating Negative-Acting Factor Encoded within the Mouse Mammary Tumor Virus Open Reading Frame Region,” Journal of Virology, 64(12):6355-6359 (1990). |
Hornsby, P.J., et al., “A Modified Procedure for Replica Plating of Mammalian Cells Allowing Selection of Clones Based on Gene Expression,” BioTechniques, 12(2):244-249 (1992). |
Wintersperger, S., et al., “Negative-acting factor and superantigen are separable activities of the mouse mammary tumor virus long terminal repeat,” Proc. Natl. Acad. Sci. USA, 92:2745-2749 (1995). |
Salmons, B., et al., “Production of Mouse Mammary Tumor Virus upon Transfection of a Recombinant Proviral DNA into Cultured Cells,” Virology, 144:101-114 (1985). |
Donehower, L.A., et al., “Regulatory and Coding Potential of the Mouse Mammary Tumor Virus Long Terminal Redundancy,” Journal of Virology, 37(1):226-238 (1981). |
Günzburg, W.H., et al., “Retroviral Vectors Directed to Predefined Cell Types for Gene Therapy,” Biologicals, 23:5-12 (1995). |